1. Rontgen and the discovery of X-rays. Br J Radiol. 1995; 68(815): 1145-1176.doi: 10.1259/0007-1285-68-815-1145
2. Flower MA. Webb’s physics of medical imaging. CRC Press, 2012.
3. Cherry SR. The 2006 Henry N. Wagner lecture: of mice and men (and positrons) – advances in PET imaging technology. J Nucl Med. 2006; 47(11): 1735-1745.
4. Kitson SL, Cuccurullo V, Ciarmiello A, Salvo D, Mansi, L. Clinical applications of positron emission tomography (PET) imaging in medicine: oncology, brain diseases and cardiology. Curr Radiopharm. 2009; 2: 224-253.
5. Roß TL, Ametamey SM. PET chemistry: radiopharmaceuticals. In: Basic sciences of nuclear medicine. Springer Berlin Heidelberg. 2011; 103-118.
6. Cherry SR. Fundamentals of positron emission tomography and applications in preclinical drug development. J Clin Pharmacol. 2001; 41(5): 482-491. doi: 10.1177/00912700122010357
7. Nutt R. The history of positron emission tomography. Mol Imaging Biol. 2002; 1(4): 11-26. doi: 10.1016/S1095-0397- (00)00051-0
8. Brownell GL. A history of positron imaging. Website: http:// neurosurgery.mgh.harvard.edu/docs/PEThistory.pdf 1999; Accessed March 15, 2014.
9. Hung JC, Callanhan RJ. USP and PET radiopharmaceuticals: 1997 FDAMA puts standard-setting body at center of regulatory process. J Nucl Med. 2004; 45(1): 13N-14N, 16N.
10. Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to radiotherapy in head-and-neck cancer. Mol Imaging Biol. 2003; 4(5): 257-270.doi: 10.1016/s1536-1632(03)00102-1
11. Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med. 1991; 32(4): 616-622.
12. Lee C-M, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci. 2006; 27(6): 310-316. doi: http://dx.doi.org/10.1016/j. tips.2006.04.004
13. Jain M, Batra SK. Genetically engineered antibody fragments and PET imaging: A new era of radioimmunodiagnosis. J Nucl Med. 2003; 44(12): 1970-1972.
14. Beeres SLMA, Bengel FM, Bartunek J, et al. Role of imaging in cardiac stem cell therapy. J Am Coll Cardiol. 2007; 49(11): 1137-1148. doi: 10.1016/j.jacc.2006.10.072
15. von Schulthess GK. Positron emission tomography versus positron emission tomography/computed tomography: From ‘Unclear’ to ‘New-Clear’ medicine. Mol Imaging Biol. 2004; 6(4): 183-187.doi: 10.1016/j.mibio.2004.05.001
16. Surti S, Karp JS. Imaging characteristics of a 3-dimensional GSO whole-body PET camera. J Nucl Med. 2004; 45(6): 1040-1049.
17. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin of N Am. 2004; 42(6): 983-1001.doi: 10.1016/j.rcl.2004.08.012
18. Herholz K, Heiss W-D. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004; 6(4): 239-269.doi: 10.1016/j.mibio.2004.05.002
19. Jones T, Rabiner EA. The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab. 2012; 32(7): 1426-1454. doi: 10.1038/jcbfm.2012.20
20. Venneri A. Imaging treatment effects in Alzheimer’s disease. Magn Reson Imaging. 2007; 25(6): 953-968. doi: http://dx.doi.org/10.1016/j.mri.2007.02.004
21. Silverman DHS, Cummings JL, Small GW, et al. Added clinical benefit of incorporating 2-Deoxy-2-[18F]Fluoro-DGlucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002; 4(4): 283-293.
22. Nordberg A. PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol. 2004; 3(9): 519-527. doi: http://dx.doi. org/10.1016/S1474-4422(04)00853-1
23. Kitson SL. 5-Hydroxytyptamine (5-HT) receptor ligands. Curr Pharma Design. 2007; 13(25): 2621-2637. doi: 10.2174/138161207781663000#sthash.AYCWvomF.dpuf
24. Klunk WE, Engler H, Nordberg A. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann of Neurol. 2004; 55(3): 306-319. doi: 10.1002/ana.20009
25. U.S. Food and Drug Administration Press Release. FDA approves second brain imaging drug to help evaluate patients for Alzheimer’s disease, dementia, 2013. http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm372261.htm; Accessed 2014.
26. U.S. Food and Drug Administration Press Release. FDA approves imaging drug Amyvid, 2012. http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm299678.htm; Accessed 2014.
27. Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007; 30(5): 194-202. doi: http://dx.doi.org/10.1016/j.tins.2007.03.006
28. Ravina B, Eidelberg D, Ahlskog JE. et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005; 64(2): 208-215.doiDOI: 10.1212/01.WNL.0000149403.14458.7F
29. Cliffe IA. A retrospect on the discovery of WAY-1000635 and the prospect for improved 5-HT1A receptor PET radioligands. Nucl Med Biol. 2000; 27(5): 441-447.doi: 10.1016/s0969-8051(00)00109-8
30. Kang KW, Lee DS, Cho JH, et al. Quantification of F-18 FDG PET images in temporal lobe epilepsy patients using probabilistic brain atlas. Neuroimage. 2001; 14(1 Pt 1): 1-6. doi: 10.1006/nimg.2001.0783
31. Bouvard S, Costes F, Bonnefoi F, et al. Seizure-related short-term plasticity of benzodiazepine receptors in parial epilepsy: a [11C]flumazenil – PET study. Brain. 2005; 128(Pt 6): 1330-1343. doi: http://dx.doi.org/10.1093/brain/awh470
32. Chunying Wu, Changing W, Daniela P, et al. A novel PET marker for in vivo quantification of myelination. Bioorg Med Chem. 2010; 18(24): 8592-8599. doi: 10.1016/j. bmc.2010.10.018
33. Schroeter M, Dennin MA, Walberer M, et al. Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F]FDG-PET study. J Cereb Blood Flow Metab. 2009; 29(6): 1216-1225. doi: 10.1038/jcbfm.2009.36
34. Riley C, Azevedo C, Bailey M, Pelletier. Clinical applications of imaging disease burden in multiple sclerosis. Expert Rev Neurother. 2012; 12(3): 323-333. doi: 10.1586/ern.11.196